Related references
Note: Only part of the references are listed.FBXW5 acts as a negative regulator of pathological cardiac hypertrophy by decreasing the TAK1 signaling to pro-hypertrophic members of the MAPK signaling pathway
Xuejun Hui et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2021)
Curcumin analogue C66 attenuates obesity-induced myocardial injury by inhibiting JNK-mediated inflammation
Lin Ye et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Crosstalk between the renin-angiotensin system and the endoplasmic reticulum stress in the cardiovascular system: Lessons learned so far
Vinicius Sepulveda-Fragoso et al.
LIFE SCIENCES (2021)
Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1
Jing Zhao et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Myocardial Angiotensin Metabolism in End-Stage Heart Failure
Noemi Pavo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Role of inflammatory chemokines in hypertension
Tomasz P. Mikolajczyk et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3
Shiju Ye et al.
CIRCULATION RESEARCH (2020)
MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy
Yi Wang et al.
NATURE COMMUNICATIONS (2020)
Activation of CREB Protein With Tabersonine Attenuates STAT3 During Atherosclerosis in Apolipoprotein E-Deficient Mice
Sen Shi et al.
DOSE-RESPONSE (2020)
The immunoproteasome catalytic β5i subunit regulates cardiac hypertrophy by targeting the autophagy protein ATG5 for degradation
Xin Xie et al.
SCIENCE ADVANCES (2019)
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
Lauren B. Arendse et al.
PHARMACOLOGICAL REVIEWS (2019)
Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy-associated cardiomyopathy
Yi Wang et al.
CELL AND BIOSCIENCE (2019)
Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway
Hai-han Liao et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination
Depeng Zhang et al.
BIOCHEMICAL PHARMACOLOGY (2018)
MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway
Jibo Han et al.
BASIC RESEARCH IN CARDIOLOGY (2017)
The role of hybrid ubiquitin chains in the MyD88 and other innate immune signalling pathways
Philip Cohen et al.
CELL DEATH AND DIFFERENTIATION (2017)
Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway
Chang-Yi Li et al.
BASIC RESEARCH IN CARDIOLOGY (2016)
Mnk1 (Mitogen-Activated Protein Kinase-Interacting Kinase 1) Deficiency Aggravates Cardiac Remodeling in Mice
Yuan Yuan et al.
HYPERTENSION (2016)
Olmesartan ameliorates pressure overload-induced cardiac remodeling through inhibition of TAK1/p38 signaling in mice
Lianpin Wu et al.
LIFE SCIENCES (2016)
The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling
Yan-Xiao Ji et al.
NATURE COMMUNICATIONS (2016)
Ornamental Exterior versus Therapeutic Interior of Madagascar Periwinkle (Catharanthus roseus): The Two Faces of a Versatile Herb
Naghmeh Nejat et al.
TheScientificWorldJOURNAL (2015)
TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways
Lei Li et al.
SCIENTIFIC REPORTS (2015)
Ornamental Exterior versus Therapeutic Interior of Madagascar Periwinkle (Catharanthus roseus): The Two Faces of a Versatile Herb
Naghmeh Nejat et al.
Scientific World Journal (2015)
The Global Health and Economic Burden of Hospitalizations for Heart Failure Lessons Learned From Hospitalized Heart Failure Registries
Andrew P. Ambrosy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: Therapeutic perspectives
Sabzali Javadov et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Targeting of TAK1 in inflammatory disorders and cancer
Hiroaki Sakurai
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload
Norimichi Koitabashi et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Tumor Suppressor A20 Protects Against Cardiac Hypertrophy and Fibrosis by Blocking Transforming Growth Factor-β-Activated Kinase 1-Dependent Signaling
He Huang et al.
HYPERTENSION (2010)
Specification of the NF-κB transcriptional response by p65 phosphorylation and TNF-induced nuclear translocation of IKKε
Rita Moreno et al.
NUCLEIC ACIDS RESEARCH (2010)
Direct activation of protein kinases by unanchored polyubiquitin chains
Zong-Ping Xia et al.
NATURE (2009)
Cardiac fibroblasts: At the heart of myocardial remodeling
Karen E. Porter et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Role of the renin-angiotensin system in vascular inflammation
Chiara Marchesi et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
A direct interaction between TGFβ activated kinase 1 and the TGFβ type II receptor:: Implications for TGFβ signalling and cardiac hypertrophy
SJ Watkins et al.
CARDIOVASCULAR RESEARCH (2006)
TAK1 is a ubiquitin-dependent kinase of MKK and IKK
C Wang et al.
NATURE (2001)
TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice
D Zhang et al.
NATURE MEDICINE (2000)